UF BPA Appendix for the Aug 2013 DoD P&T Meeting

Uniform Formulary Price Quotes and
Uniform Formulary Blanket Purchase Agreements (BPA)

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF BPA price quotes are to be submitted by the Company.

The Company must submit a complete UF BPA price quote for each NDC that applies to the Company's pharmaceutical agent(s) in a given drug class.

Medications placed on the Uniform Formulary but not BCF or ECF are available for the local Military Treatment Facility P&T to decide whether to place on their individual formulary.

No grandfathering: a prior authorization process, would require all patients, regardless of past medication history to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user through a MTF pharmacy or TMOP.

Suite: Each manufacturer will be allowed to designate what strips are in their group of strips known as a suite. Only one bid submission per manufacturer will be allowed. All strips within a suite must have the same price. The government will accept the entire suite, or not at all. All NDC's within the suite must have a permanent FSS. If NDC's are included that do not have a permanent FSS then the entire bid will be considered non-responsive and returned to the bidder.

Medical Necessity for this class may include but is not limited to:

1. The patient reasonably would not be able to use a formulary blood glucose meter and strips appropriately or effectively instead of the requested blood glucose meter and formulary excluded strips.
2. The patient has a documented physical or mental health disability requiring a special monitor (e.g. visual impairment).
3. The patient is using the Medtronic Mini Med Paradigm insulin pump with the One Touch Ultra Link meter (OneTouch Ultra test strips) or the patient is using the One Touch Ping insulin pump and One Touch Ping meter (OneTouch Ultra test strips).
4. The patient is receiving peritoneal dialysis or the intravenous immune globulin (IVIG) preparation Octagam and the provider is concerned about the glucose dehydrogenase-pyrroloquinolinequinone interaction (GDH-PQQ).

Requirements:

1. General Requirements
   - Test strips
     - Must be available at all 3 Points of Service
     - Must be Trade Agreement Act-compliant
   - Meters
     - Manufacturer must have a process to supply meters to beneficiaries at no cost.
     - Must be Trade Agreement Act-compliant
2. Meet the new minimum technical requirements

Feature	Minimum Requirements
Accuracy	FDA/ISO standard
Sample size	≤ 1 microliter
Alternate site testing	>1 site (palm, forearm, etc)
Result time	≤ 10 seconds
Memory	≥ 250 readings
Ease of use	Coding/calibration*, large visual display, dexterity
Customer support	24-hour phone help line†
Downloading capability	Mandatory
Data management capability	Mandatory

* Require low risk of coding/calibration errors; exclude meters with manual coding
† 24-hour helpline required for OCONUS beneficiaries

The following NDCs are in this Suite:

NDC	Drug Name	Strength	Dosage Form	Package Size

Class: SELF MONITORING BLOOD GLUCOSE SYSTEMS			
Class Note(s): Each manufacturer will be allowed to designate what strips are in their group of strips known as a suite. Only one bid submission per manufacturer will be allowed. All strips within a suite must have the same price. A Basic Core Formulary agent will be selected from the winning suite.			
Step Therapy Addendum: "No grandfathering" has been designated for this class.			
Condition Set #	**Category**	**One of (X) Number of Suites**	**Military Treatment Facility and Mail Order Price per Strip**
1304BGNO1T2BS1X	Uniform Formulary and Tier 2 Before Step Therapy	1	